What’s new with the “pace-and-ablate” strategy?

Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with increased morbidity and mortality. The guideline of the European Society for Cardiology (ESC), which was updated last year, uses current evidence to show in which cases intensified drug therapy is not sufficient and under which conditions implantation of a pacemaker in combination with atrioventricular (AV) node ablation should be considered. The “pace-and-ablate” strategy is currently being investigated in various AF patient subpopulations.